Special Issue "Molecular Alterations in Thyroid Cancer – With Special Focus on Diagnosis, Prognosis and Treatment"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 June 2020.

Special Issue Editors

Guest Editor
Dr. Christofer Juhlin Website E-Mail
1. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
2. Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden
Interests: follicular thyroid cancer; anaplastic thyroid cancer; endocrine neoplasia; endocrine pathology; next-generation sequencing; histopathology; diagnostic and prognostic markers
Guest Editor
Dr. Adam Stenman Website E-Mail
1. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
2. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
3. Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden
Interests: papillary thyroid cancer; follicular thyroid cancer; endocrine surgery; next-generation sequencing; genetic aberrations in endocrine neoplasia; prognostic markers
Guest Editor
Prof. Dr. Jan Zedenius Website E-Mail
1. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
2. Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden
Interests: medullary thyroid cancer; anaplastic thyroid cancer; hereditary syndromes; translational research; therapeutics; endocrine surgery

Special Issue Information

Dear Colleagues,

Thyroid cancer is the most common endocrine malignancy with an annual incidence of about 60,000 cases in the US and shows an increased incidence globally. The disease entity is multifaceted, and although the majority of well-differentiated forms of thyroid cancer (papillary thyroid cancer, PTC, and follicular thyroid cancer, FTC) exhibit good prognosis, other forms of thyroid cancer are often associated with dismal outcomes (poorly differentiated thyroid cancer, PDTC, and anaplastic thyroid cancer, ATC). The underlying genetic mechanisms driving thyroid cancer is only partly understood, but the advent of next-generation sequencing techniques has greatly facilitated the detection of recurrent genomic alterations of importance for disease development—of which some could be of direct clinical value.

This Special Issue will focus on molecular studies aimed at providing aid to three commonly encountered clinical dilemmas, namely (1) the diagnostic predicaments in thyroid cancer (most notably―but not limited to―the distinction of benign and malignant follicular thyroid tumors), (2) the enablement to prognosticate thyroid cancer (for example, to pinpoint the subset of thyroid cancer that recur and/or spread to distant sites) and (3) the therapeutic quandaries regarding metastatic thyroid cancer and less differentiated forms of the disease (PDTC, ATC). Further, submissions aimed at increasing our understanding of inherited forms of thyroid cancer are also warmly welcome.

Dr. Carl Christofer Juhlin
Dr. Adam Stenman
Prof. Dr. Jan Zedenius
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Papillary thyroid carcinoma
  • Follicular thyroid carcinoma
  • Medullary thyroid carcinoma
  • Anaplastic thyroid carcinoma
  • Thyroid tumors
  • Diagnosis
  • Prognostication
  • Treatment
  • Molecular genetics
  • Next-generation sequencing
  • Mutation
  • Omics
  • Clinical biomarker

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer
Cancers 2019, 11(8), 1154; https://doi.org/10.3390/cancers11081154 - 12 Aug 2019
Abstract
Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in [...] Read more.
Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levels of FGF21, FGF receptors (FGFRs), and β-klotho (KLB) were investigated in human thyroid tissues. The cell viability, migrating cells, and invading cells were measured in PTC cells after treatment with recombinant FGF21. Higher serum levels of FGF21 were found in patients with thyroid cancer than in control participants, and were significantly associated with body mass index (BMI), fasting glucose levels, triglyceride levels, tumor stage, lymphovascular invasion, and recurrence. Serum FGF21 levels were positively correlated with the BMI in patients with PTC, and significantly associated with recurrence. Recombinant FGF21 led to tumor aggressiveness via activation of the FGFR signaling axis and epithelial-to-mesenchymal transition (EMT) signaling in PTC cells, and AZD4547, an FGFR tyrosine kinase inhibitor, attenuated the effects of FGF21. Hence, FGF21 may be a new biomarker for predicting tumor progression, and targeting FGFR may be a novel therapy for the treatment of obese patients with PTC. Full article
Show Figures

Figure 1

Back to TopTop